The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
An emergency meeting will be held today to discuss the Scottish government's next steps following the UK's decision to leave the EU.
As Muse made their third headlining appearance at Glastonbury, Jess Glynne appeared for her debut while Damon Albarn also starred.
The Pentagon will announce the reversal of policy as soon as next month, US officials claimed.